The Technical Analyst
Select Language :

Corbus Pharmaceuticals [CRBP]

Exchange: NASDAQ Global Market Sector: Healthcare Industry: Biotechnology

Stock Price, Forecast, Insider, Ratings, Fundamentals & Signals

Corbus Pharmaceuticals is listed at the NASDAQ Exchange

-3.06% $0.884

Last updated: 28 Nov 2021 @ 17:00 pm


FUNDAMENTALS
MarketCap: 110.70 mill
EPS: -0.387
P/E: 0.000
Earnings Date: Nov 12, 2021
SharesOutstanding: 125.23 mill
Avg Daily Volume: 1.042 mill
RATING 2021-11-26
A-
Buy
RATING DETAILS
Rating CashFlow: Strong Buy
Return On Equity: Neutral
Return On Asset: Neutral
DE: Buy
P/E: Strong Sell
Price To Book: Strong Buy
QUARTER GROWTHS
2/203/204/201/212/213/21
Revenue
Gr.Profitn/an/an/an/a
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE 0.000 | sector: PE 371.73
PE RATIO: COMPANY / INDUSTRY
0.00x
Company: PE 0.000 | industry: PE 479.09

Insider Trading

Date Person Action Amount type
2021-06-17 Holmer Alan F Buy 58 200 Stock Option (right to buy)
2021-06-17 Jacques Rachelle Suzanne Buy 58 200 Stock Option (right to buy)
2021-06-17 Salzmann Peter Buy 58 200 Stock Option (right to buy)
2021-06-17 Catlin Avery W Buy 58 200 Stock Option (right to buy)
2021-06-17 Jenkins John Kenneth Buy 58 200 Stock Option (right to buy)
INSIDER POWER
78.13
Last 100 transactions
Buy: 7 586 195 | Sell: 586 066

Forecast: 14:40 - $0.889

Live Trading Signals (every 1 min)

Forecast 1: 13:10 - $0.887
Forecast 2: 14:00 - $0.891
Forecast 3: 14:40 - $0.889
SCORE
-4.75
Sell
Score Algorithm Version: 0.9M
Last version updated: Thurs 28th Oct 2021
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $0.884 (-3.06% )
Volume 0.356 mill
Avg. Vol. 1.042 mill
% of Avg. Vol 34.18 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Corbus Pharmaceuticals Holdings Inc

Last 12 Months

Last 12 months chart data with high, low, open and close for Corbus Pharmaceuticals Holdings Inc

RSI

Intraday RSI14 chart for Corbus Pharmaceuticals Holdings Inc
The Live Chart for Corbus Pharmaceuticals Holdings Inc
Profile picture for
            Corbus Pharmaceuticals Holdings Inc

CRBP

Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid drug that is in Phase III clinical trials for the treatment of systemic sclerosis and dermatomyositis, and in Phase IIb clinical trials to treat systemic lupus erythematosus and cystic fibrosis. The company is also developing CRB-4001, a peripherally-restricted CB1 inverse agonist, for nonalcoholic steatohepatitis and other fibrotic diseases. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, which includes the Jenrin library of approximately 600 compounds and multiple issued and pending patent filings; and strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was founded in 2009 and is based in Norwood, Massachusetts.

Last 10 Buy Signals
Date Signal @
XRPUSDNov 28 - 11:510.918
XRPUSDNov 28 - 11:440.914
BTCUSDNov 28 - 11:2954 102
DOGEUSDNov 28 - 11:29$0.198
XRPUSDNov 28 - 11:230.920
XRPUSDNov 28 - 11:100.924
XRPUSDNov 28 - 10:590.926
XRPUSDNov 28 - 10:550.928
BTCUSDNov 28 - 10:5354 420
DOGEUSDNov 28 - 10:46$0.201

Stock Peers

Company Price Change
CRBP0.884-3.06%
ASLN1.5302.68%
CDMOP25.060.04%
CMMB8.87-0.22%
CTIC2.485.98%
KIN9.250.11%
OBSV2.240.00%
ORPH3.30-2.94%
SMTI28.65-1.21%
TCDA7.40-3.77%
VTVT1.340-2.19%

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.